SDC VS DMAC Stock Comparison

Performance

SDC
10/100

SDC returned -32.98% in the last 12 months. Based on SPY's performance of -7.17%, its performance is below average giving it a score of 10 of 100.

DMAC
100/100

DMAC returned 111.21% in the last 12 months. Based on SPY's performance of 13.09%, its performance is above average giving it a score of 100 of 100.

Sentiment

SDC
70/100

SDC had a bullish sentiment score of 69.85% across Twitter and StockTwits over the last 12 months. It had an average of 139.63 posts, 16,373.01 comments, and 17,465.68 likes per day.

DMAC

"Sentiment" not found for DMAC

Technicals

SDC
82/100

SDC receives a 82 of 100 based on 14 indicators. 11 are bullish, 2 are bearish.

DMAC
57/100

DMAC receives a 57 of 100 based on 14 indicators. 7 are bullish, 5 are bearish.

Earnings

SDC
10/100

SDC has missed earnings 9 times in the last 20 quarters.

DMAC
27/100

DMAC has missed earnings 5 times in the last 20 quarters.

Profit

SDC
10/100

Out of the last 19 quarters, SDC has had 0 profitable quarters and has increased their profits year over year on 0 of them.

DMAC
10/100

Out of the last 20 quarters, DMAC has had 0 profitable quarters and has increased their profits year over year on 1 of them.

Volatility

SDC
50/100

SDC has had an average amount of volatility over the last 12 months giving it a score of 50 of 100.

DMAC
49/100

DMAC has had a lower than average amount of volatility over the last 12 months giving it a score of 49 of 100.

All score calculations are broken down here to help you make more informed investing decisions

SmileDirectClub, Inc. Class A Common Stock Summary

Nasdaq / SDC

Healthcare

Medical Instruments & Supplies

SmileDirectClub, Inc., an oral care company, offers clear aligner therapy treatment. The company manages the end-to-end process, which include marketing, aligner manufacturing, fulfillment, treatment by a doctor, and monitoring through completion of their treatment with a network of approximately 250 licensed orthodontists and general dentists through its teledentistry platform, SmileCheck in the United States, Puerto Rico, Canada, Australia, the United Kingdom, New Zealand, Ireland, Hong Kong, Germany, Singapore, France, Spain, and Austria. It also offers aligners, impression and whitening kits, whitening gels, and retainers; and toothbrushes, toothpastes, water flossers, SmileSpa, and various ancillary oral care products. The company was founded in 2014 and is headquartered in Nashville, Tennessee.

DiaMedica Therapeutics Inc. Common Stock Summary

Nasdaq / DMAC

Healthcare

Biotechnology

DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, develops treatments for neurological and kidney diseases. The company's lead drug candidate is DM199, a recombinant human tissue kallikrein-1 protein, which is in Phase 2 REDUX trial for the treatment of patients with moderate or severe chronic kidney disease caused by Type I or Type II diabetes; and Phase 2/3 REMEDY2 trials for the treatment of patients with acute ischemic stroke. It is also developing DM300 that is in pre-clinical stage for the treatment of inflammatory diseases. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.

Power up your portfolio